Navigation Links
Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Wins 2009 Silver Innovation Award
Date:10/20/2009

EAST RUTHERFORD, N.J., Oct. 20 /PRNewswire-FirstCall/ -- Cambrex Corporation (NYSE: CBM) announced today that it won the Silver Innovation Award at the 2009 CPhI Event for its Continuous-Flow Microwave-Assisted Organic Synthesis (CFMAOS) technology. The award was accepted by Dr. Jayne E. Muir (Market Research & New Technologies - Europe), who presented the technology to a panel of judges at this important pharmaceutical ingredients exhibition in Madrid, Spain on October 13, 2009.

The CPhI Innovation Awards give companies the chance to showcase the best of their R&D efforts and are widely recognized as premier awards in the field of international pharmaceutical manufacturing. This year had a particularly strong number and quality of entries and the six shortlisted companies spanned a wide range of subjects, from biopolymers to colors and coatings. On accepting the award, Dr. Muir said, "The area of flow chemistry is very exciting at the moment, and we were pleased with the interest and number of questions about the CaMWave(TM) technology following the presentation and throughout CPhI."

The CF-MAOS technology represents a dual technological breakthrough, allowing both the scale-up of microwave-assisted chemistry and the handling of heterogeneous mixtures in continuous-flow. This new technology will finally bring the benefits of both technologies out of the laboratory and into production. The CaMWave(TM) KiloLAB flow reactor is capable of manufacturing in excess of 20 kilograms of product per day, and larger reactors will generate more than one hundred metric tons of product per year. This versatile technology facilitates faster, cleaner, more reliable reactions, leading to improved productivity and lower manufacturing costs.

If you would like to inquire further about this technology, please contact Dr. Jayn
'/>"/>

SOURCE Cambrex Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. CLIA Waiver Submitted for Rapid HIV Test Employs StatSures Barrel Technology
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. Local Medicare Contractors Expand Hypertension Coverage for CardioDynamics BioZ(R) ICG Technology
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
7. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
8. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
9. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
10. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
11. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...rdingtoMillenniumResearchGroup(MRG),theglobalautho...y$3billionUSmarketfortraumafixationdeviceswillcont...recenteconomicslowdown.MRG,s USMarketsforTraumaDev...lydynamicoverthenextfiveyears,withcompetitorsintro...mentsofthetraumafixationmarket,fuelingmarketgrowth...
(Date:11/25/2009)...er.comannouncesthatanewmarketresearchreportisavail...USMarketTrends&Analysis http://www.reportlink...et-Trends--Analysis.html ,, TheUSintranasaldru...capplicationsfromthedeliveryofconventionallocalthe...gs.Thefutureofthetechnologyhingesontotheeffectivee...
(Date:11/24/2009)...ChindexInternational,Inc.,("Chindex")(Nasdaq: CHDX...althcareproductsandservicesinthePeople,sRepublicof...stAnnualPiperJaffray,"Unplugged"HealthCareConferen...el. , Managementiscurrentlyscheduledtopresent...-onemeetingsthroughouttheday.Awebcast,ofthepresent...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5Chindex International to Present at Piper Jaffray Health Care Conference 2Prism and Medical College of Wisconsin investigators receive 241 6 million NIH grant to develop advanced medical imaging tools 61424 1Prism and Medical College of Wisconsin investigators receive 241 6 million NIH grant to develop advanced medical imaging tools 61424 2Prism and Medical College of Wisconsin investigators receive 241 6 million NIH grant to develop advanced medical imaging tools 61424 3Shire announces publication of open label study on coadministration of INTUNIV with stimulants 61419 1Shire announces publication of open label study on coadministration of INTUNIV with stimulants 61419 2Shire announces publication of open label study on coadministration of INTUNIV with stimulants 61419 3Study shows link between influenza virus and fever 10734 1Study shows link between influenza virus and fever 10734 2
(Date:11/25/2009)...,Nov.25/PRNewswire-FirstCall/-- OnyxPharmaceutica...willhosttwoinvestoreventsinDecember: ,, ASHBr...m.ET ,, Principalinvestigatorswilldiscussdata...rrefractorymultiplemyeloma,asfeaturedatthe51stAmer...tioninNewOrleans,LA.Theteleconferencewillbeginat9:...
(Date:11/25/2009).../PRNewswire-USNewswire/--TheBlackAIDSInstituterece...veleadershipfor2010. ,, ThenewBoardMembersareah...olicy,law,finance,governmenthealthprograms,editori...omawiderangeofpersonalbackgroundsincludingbothhete...emselves,andrepresentingmultipleagegroups. ,, (...
(Date:11/25/2009)...y that grew out of a collaboration between UCLA en...e to the nearly 10 million Americans who suffer fr... as hardening of the arteries, peripheral arterial...in which narrowed arteries reduce blood flow to th...r vascular disease, heart attack and stroke, and i...
(Date:11/25/2009)...uld lead mothers to overlook needed care, study fi...ws) -- A mother,s depression can worsen her child,...six-month study of 262 black mothers and their chi...epressive symptoms had more frequent asthma sympto...e symptoms had less frequent asthma symptoms. ,...
(Date:11/25/2009)...ntShownforthe4thStraightYear ,, WASHINGTON,No...iance-Georgia(LCA-GA)issuedthe 4thAnnualReportCard...ingmadeagainstthislethaldiseaseinthestateofGeorgia...nationalorganizationdedicatedexclusivelytopatients...gcancer. ,, (Logo: http://www.newscom.com/cgi-b...
Breaking Medicine News(10 mins):Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Mom's Depression May Worsen Child's Asthma 2Health News:Lung Cancer Alliance-Georgia Issues 4th Annual State-Specific Report Card on Lung Cancer 2
..., SWITZERLAND, March 13 /PRNewswire-FirstCall/ - N...olly-owned subsidiary of Neurochem,Inc. (NASDAQ: ...king new,initiatives to pursue the drug developmen...s. Neurochem,s decision to build,upon its eprodisa...
...y Outlines Milestones for 2008 -, EMERYVILLE, Cal...y announced financial results for the fourth quart... Quarter Results, The company reported revenues f...riod in 2006, is due primarily,to the recognition ...
... results of combination therapy VELCADE, melphalan...mission rate with 85 percent of patients ... Mass., March 13 Millennium,Pharmaceuticals, Inc....d prednisone (VcMP) in newly diagnosed multiple,my...
...ntone Hosts Fundraiser, NEW YORK, March 13 DKMS ...awford at their "Linked Against Leukemia Gala" on,...ity. The 2nd annual,black-tie affair is a benefit ...te more than 13,000 transplants., The evening wil...
...ured majority of convertible notes due June 2008 ...orward Projects Zevalin(R) net sales revenues ...e-Cell Therapeutics,Inc. (CTI) (Nasdaq: CTIC ; MT...ompletion of Zevalin(R) (Ibritumomab Tiuxetan) acq...
...UVER Shining synchrotron light on environmental q... a Memorandum of Understanding (MOU) signed today ...Light Source (CLS) and MIRARCO Mining Innovation. ...his collaboration will undoubtedly be of tremendou...
Other Medicine News:Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 2Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 3Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 4Health News:Bionovo Announces 2007 Financial Results and Highlights 2Health News:Bionovo Announces 2007 Financial Results and Highlights 3Health News:Bionovo Announces 2007 Financial Results and Highlights 4Health News:Bionovo Announces 2007 Financial Results and Highlights 5Health News:Bionovo Announces 2007 Financial Results and Highlights 6Health News:Bionovo Announces 2007 Financial Results and Highlights 7Health News:Bionovo Announces 2007 Financial Results and Highlights 8Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 2Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 3Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 4Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 5Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 6Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 7Health News:Super Model Cindy Crawford will be Honored at DKMS 'Linked Against Leukemia Gala' on May 7th at Capitale 2Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 2Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 3Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 4Health News:MIRARCO, Canadian Light Source agreement lights way to greener mining 2
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
... Laboratories is a national reference laboratory a...earch and development. ARUP offers an extensive te... in clinical and anatomic pathology. Owned by the ...lude more than half of the nation's university tea...
Medicine Products: